14-day Premium Trial Subscription Sign Up For FreeGet Free

Stock Market Week 20 - The Game Is On! Click to watch.

Alnylam Pharmaceuticals Stock Forecast

NASDAQ:ALNY BUY SELL

$124.87 (-1.27%)

Volume: 939.591k

Closed: May 16, 2022

Hollow Logo Score: -4.591

Alnylam Pharmaceuticals Stock Forecast

BUY SELL NASDAQ:ALNY
$124.87 (-1.27%)

Volume: 939.591k

Closed: May 16, 2022

Score Hollow Logo -4.591

Alnylam Pharmaceuticals Stock Forecast NASDAQ:ALNY

Price Target and Analyst Ratings

Historical Ratings

Date Upside / Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
2022-05-02 244.36% HC Wainwright & Co. $400.00 $430.00 Maintains Buy
2022-04-29 36.14% Morgan Stanley $178.00 $170.00 Maintains Equal-Weight
2022-04-29 68.98% Citigroup $223.00 $211.00 Maintains Buy
2022-04-29 32.94% BMO Capital $171.00 $166.00 Maintains Market Perform
2022-04-29 -23.12% SVB Leerink $103.00 $96.00 Maintains Market Perform
2022-04-25 42.55% Morgan Stanley $210.00 $178.00 Downgrades Overweight Equal-Weight
2022-04-12 220.33% HC Wainwright & Co. $350.00 $400.00 Maintains Buy
2022-03-01 78.59% Citigroup $223.00 Initiates Coverage On Buy
2022-02-23 68.17% Morgan Stanley $215.00 $210.00 Maintains Overweight
2022-02-11 -17.51% SVB Leerink $109.00 $103.00 Maintains Market Perform
2022-02-03 36.14% Guggenheim $170.00 Upgrades Neutral Buy
2022-01-28 -12.71% SVB Leerink $108.00 $109.00 Maintains Market Perform
2022-01-20 180.29% HC Wainwright & Co. $250.00 $350.00 Maintains Buy
2022-01-18 72.18% Morgan Stanley $226.00 $215.00 Maintains Overweight
2022-01-03 66.57% Piper Sandler $181.00 $208.00 Upgrades Neutral Overweight
2021-11-22 80.19% RBC Capital $144.00 $225.00 Upgrades Sector Perform Outperform
2021-11-22 118.63% Goldman Sachs $273.00 Upgrades Neutral Buy
2021-11-22 64.17% Needham $180.00 $205.00 Maintains Buy
2021-11-01 60.17% Oppenheimer $200.00 Upgrades Perform Outperform
2021-10-29 80.99% Morgan Stanley $242.00 $226.00 Maintains Overweight
2021-10-29 60.17% Chardan Capital $190.00 $200.00 Maintains Buy
2021-10-28 -13.51% SVB Leerink $104.00 $108.00 Maintains Market Perform
2021-10-12 93.8% Morgan Stanley $234.00 $242.00 Maintains Overweight
2021-10-04 72.18% UBS $141.00 $215.00 Upgrades Neutral Buy
2021-08-27 56.96% BMO Capital $174.00 $196.00 Maintains Market Perform
2021-08-13 100.21% HC Wainwright & Co. $235.00 $250.00 Maintains Buy
2021-08-04 87.39% Morgan Stanley $224.00 $234.00 Maintains Overweight
2021-08-04 72.98% Barclays $196.00 $216.00 Maintains Overweight
2021-08-04 44.95% Piper Sandler $181.00 Downgrades Overweight Neutral
2021-07-16 79.39% Morgan Stanley $205.00 $224.00 Maintains Overweight
2021-04-30 64.17% Morgan Stanley $206.00 $205.00 Maintains Overweight
2021-02-22 29.73% Guggenheim $162.00 Downgrades Buy Neutral
2021-02-12 64.97% Morgan Stanley $203.00 $206.00 Maintains Overweight
2021-02-12 56.96% Barclays $162.00 $196.00 Maintains Overweight
2021-02-12 40.15% Citigroup $170.00 $175.00 Downgrades Buy Neutral
2021-02-12 88.2% HC Wainwright & Co. $225.00 $235.00 Maintains Buy
2021-02-12 44.15% Needham $160.00 $180.00 Maintains Buy
2021-01-25 48.15% BMO Capital $185.00 Downgrades Outperform Market Perform
2020-11-25 62.57% Morgan Stanley $200.00 $203.00 Maintains Overweight
2020-11-25 -25.52% SVB Leerink $91.00 $93.00 Maintains Market Perform
2020-11-24 -27.12% SVB Leerink $90.00 $91.00 Maintains Market Perform
2020-11-06 60.17% Morgan Stanley $197.00 $200.00 Maintains Overweight
2020-10-15 25.73% B of A Securities $160.00 $157.00 Maintains Buy
2020-09-08 36.14% Citigroup $170.00 Initiates Coverage On Buy
2020-08-11 24.93% Oppenheimer $162.00 $156.00 Downgrades Outperform Perform
2020-08-07 57.76% Morgan Stanley $199.00 $197.00 Maintains Overweight
2020-08-07 -27.93% SVB Leerink $89.00 $90.00 Maintains Market Perform
2020-07-15 59.37% Morgan Stanley $162.00 $199.00 Maintains Overweight
2020-05-28 -2.3% UBS $111.00 $122.00 Maintains Neutral
2020-05-13 20.12% RBC Capital $150.00 Initiates Coverage On Sector Perform
2020-05-07 24.93% Barclays $143.00 $156.00 Maintains Overweight
2020-05-07 36.94% BMO Capital $145.00 $171.00 Maintains Outperform
2020-05-07 29.73% Oppenheimer $140.00 $162.00 Maintains Outperform
2020-05-07 29.73% Morgan Stanley $148.00 $162.00 Maintains Overweight
2020-05-07 9.71% JP Morgan $133.00 $137.00 Downgrades Overweight Neutral
2020-05-06 28.13% Needham $135.00 $160.00 Maintains Buy
2020-04-14 -40.74% Nomura $74.00 $74.00 Maintains Reduce
2020-03-19 60.17% Berenberg $200.00 Initiates Coverage On Buy
2020-02-11 -39.94% Nomura $62.00 $75.00 Maintains Reduce
2020-02-07 18.52% Morgan Stanley $150.00 $148.00 Maintains Overweight
2019-12-19 52.16% Chardan Capital $150.00 $190.00 Maintains Buy
2019-12-18 40.95% Cantor Fitzgerald $159.00 $176.00 Reiterates Overweight
2019-12-17 20.12% Morgan Stanley $141.00 $150.00 Maintains Overweight
2019-11-25 14.52% BMO Capital $138.00 $143.00 Maintains Outperform
2019-11-21 4.91% Barclays $125.00 $131.00 Maintains Overweight
2019-11-21 27.33% Cantor Fitzgerald $150.00 $159.00 Maintains Overweight
2019-11-21 12.92% Morgan Stanley $124.00 $141.00 Maintains Overweight
2019-11-21 10.51% BMO Capital $128.00 $138.00 Maintains Outperform
2019-11-20 2.51% Oppenheimer $128.00 Initiates Coverage On Outperform
2019-11-13 -11.91% B of A Securities $110.00 Initiates Coverage On Buy
2019-09-04 -23.12% UBS $95.00 $96.00 Maintains Neutral
2019-09-03 16.12% Piper Sandler $142.00 $145.00 Maintains Overweight
2019-08-07 -0.7% Morgan Stanley $126.00 $124.00 Maintains Overweight
2019-05-23 -35.93% Goldman Sachs $80.00 Assumes Neutral

ALNY Stock Trend

The stock lies in the lower of a very wide and falling trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $119.24 is broken, it will firstly indicate a stronger fall rate.

Given the current short-term trend, the stock is expected to fall -13.00% during the next 3 months and, with a 90% probability hold a price between $103.74 and $137.04 at the end of this 3-month period.

Data

Date Bottom Mid Top
2022-05-18 $118.85 $137.99 $157.12
2022-05-19 $118.46 $137.59 $156.73
2022-05-20 $118.07 $137.20 $156.34
2022-05-23 $117.67 $136.81 $155.95
2022-05-24 $117.28 $136.42 $155.55
2022-05-25 $116.89 $136.03 $155.16
2022-05-26 $116.50 $135.63 $154.77
2022-05-27 $116.11 $135.24 $154.38
2022-05-31 $115.71 $134.85 $153.99
2022-06-01 $115.32 $134.46 $153.59
2022-06-02 $114.93 $134.07 $153.20
2022-06-03 $114.54 $133.67 $152.81
2022-06-06 $114.15 $133.28 $152.42
2022-06-07 $113.75 $132.89 $152.02
2022-06-08 $113.36 $132.50 $151.63
2022-06-09 $112.97 $132.10 $151.24
2022-06-10 $112.58 $131.71 $150.85
2022-06-13 $112.18 $131.32 $150.46
2022-06-14 $111.79 $130.93 $150.06
2022-06-15 $111.40 $130.54 $149.67
2022-06-16 $111.01 $130.14 $149.28
2022-06-17 $110.62 $129.75 $148.89
2022-06-21 $110.22 $129.36 $148.50
2022-06-22 $109.83 $128.97 $148.10
2022-06-23 $109.44 $128.58 $147.71
2022-06-24 $109.05 $128.18 $147.32
2022-06-27 $108.66 $127.79 $146.93
2022-06-28 $108.26 $127.40 $146.53
2022-06-29 $107.87 $127.01 $146.14
2022-06-30 $107.48 $126.61 $145.75

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. The company’s clinical development programs include Patisiran and Revusiran, which are in Phase III clinical trials for the treatment of transthyretin amyloidosis (ATTR); ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR for the treatment of various forms of ATTR amyloidosis; Fitusiran, an... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 108 000+ Happy Subscribers

Don't miss out on the runners!

Sign for StockInvest.us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT